[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes":587},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,367,0,25,[9,44,76,99,125,144,169,193,212,239,260,278,299,318,342,361,382,402,441,460,488,508,529,548,569],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053897",false,"NCT06007404","Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents","The Role of Circulating Meta-Inflammatory Monocytes in Adolescent Insulin Resistance","Inclusion Criteria:\n\n* Between 14 and 18 years of age\n* Tanner stage 4 or 5 (mature adult stage of puberty)\n* Normal weight (BMI ≥ 5th percentile \\& \\\u003C 85th percentile), overweight (BMI \\> 86th percentile) \\& \\\u003C 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and\u002For pre-diabetes (HbA1c \\> 5.7%)\n* For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes\n\nExclusion Criteria:\n\n* Currently pregnant\n* Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids), unless prescribed for Type 2 Diabetes management\n* Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff\n* Allergies or intolerance to milk, soy, or palm oil",true,"ALL","14 Years","18 Years",{"count":21,"type":22},175,"ESTIMATED","OBSERVATIONAL","This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.",[26,27,28,29,30],"Type 2 Diabetes","Insulin Resistance","Obesity","Metabolic Disease","PreDiabetes","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2023-09-06",{"date":39,"type":22},"2027-09",{"name":41,"class":42},"University of Michigan","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":43},"100053812","NCT07697612","Durian Consumption in Adults With Type 2 Diabetes Mellitus","Durian Consumption on Human Microbiome and Metabolome in Adults With Type 2 Diabetes Mellitus (DURIOME-T2D)","DURIOME-T2D","Inclusion Criteria:\n\n1. Age 21 to 70 years.\n2. Diagnosis of type 2 diabetes mellitus.\n3. Agrees to consume durian for 2 weeks.\n4. Body mass index 25 to 40 kg\u002Fm².\n\nExclusion Criteria:\n\n1. Known or suspected intolerance or allergy to durian.\n2. Known skin reaction to adhesives used in a continuous glucose sensor.\n3. Uncontrolled diabetes (HbA1c greater than 8.5%).\n4. Severe hypertriglyceridemia (triglycerides greater than 4.5 mmol\u002FL).\n5. Smoking.\n6. Previous gastrointestinal surgeries, including cholecystectomy, gastrectomy, bariatric surgery, or colectomy.\n7. Inflammatory bowel disease.\n8. Glomerular filtration rate less than 30 mL\u002Fmin.\n9. ALT greater than 3 times upper limit of normal.\n10. AST greater than 3 times upper limit of normal.\n11. Liver cirrhosis.\n12. Significant alcohol consumption, defined as more than 20 g\u002Fday for women and more than 30 g\u002Fday for men.\n13. Pregnant, breastfeeding, or intending to conceive during the study.\n14. Current hemorrhoids or piles causing rectal bleeding during stool passage.\n15. Systemic steroid use.\n16. Insulin use.\n17. Weight loss medications, including GLP-1 receptor agonists, orlistat, or phentermine.\n18. Antibiotic, prebiotic, probiotic, vitamin C, or traditional Chinese medicine use in the last 1 month.\n19. Uncontrolled thyroid disease.\n20. Any factor likely to limit adherence to study protocol, including dementia, substance abuse, poor appointment adherence, or family concerns regarding participation","21 Years","70 Years",{"count":54,"type":22},40,"INTERVENTIONAL",[57],"NA","This single-arm clinical trial investigates the effects of daily durian consumption on the gut microbiome, host metabolome, and glucose metrics in adults with type 2 diabetes mellitus (T2DM). Forty adults with T2DM will undergo a pre-durian phase, a durian consumption phase, and a post-durian phase, each lasting 10 to 14 days. Participants will attend five visits at Singapore General Hospital for clinical assessments, continuous glucose monitoring, fasting blood collection, stool sample collection, and dietary and stool record submission. The study aims to determine whether durian consumption alters microbiome and metabolomic profiles and whether it affects glycemic measures in adults with T2DM.",[26],[61,62,63,64,65,66],"Durian","Gut Microbiome","Metabolome","Continuous Glucose Monitoring","Precision Nutrition","Type 2 Diabetes Mellitus","NOT_YET_RECRUITING","2026-07-06",{"date":34,"type":35},{"date":71,"type":22},"2026-08",{"date":73,"type":22},"2027-12",{"name":75,"class":42},"Singapore General Hospital",{"id":77,"slug":4,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":55,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100573762","NCT06750497","Forearm Immobilization in T2D","The Impact of Short-term Forearm Immobilization on Forearm Muscle Glucose and Amino Acid Metabolism of Volunteers With or Without Type 2 Diabetes","FIT2D","Inclusion criteria\n\n* Males and females with or without diagnosed type 2 diabetes\n* Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D\n* Aged 18-80 years at the time of signing informed consent\n* 18.5 ≥ BMI ≤ 35 kg·m2\n\nExclusion criteria\n\n* Type 1 or a genetic form of diabetes\n* Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and\u002For ≥100 mmHg diastolic)\n* Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors)\n* Consumption of a low-carbohydrate diet\n* Smoking or chewing tobacco\n* Known anaemia\n* Regular use of dietary protein and\u002For amino acid supplements (\\>3 times per week)\n* Currently involved in a structured progressive resistance training program (\\>3 times per week)\n* A personal or family history of thrombosis (clots)\n* Any previous motor disorders or inborn errors in muscle and\u002For lipid metabolism\n* History of kidney disease\n* History of liver disease\n* Pregnant or breastfeeding\n* History of any drug or alcohol abuse in the past two years\n* Claustrophobia\n* Unable to give consent","80 Years",{"count":85,"type":22},26,[57],"The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.",[89,26],"Healthy","2026-07-01",{"date":92,"type":35},"2026-07-02",{"date":94,"type":35},"2024-11-21",{"date":96,"type":22},"2027-04-30",{"name":98,"class":42},"Wageningen University",{"id":100,"slug":4,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":16,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100572195","NCT06730113","Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study","Youth-onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet the following criteria according to their group:\n\nFour categories of participants will be included in this study and the inclusion criteria for each group are given below:\n\n1. Participants with Y-T2DM\n\n1a.Age 12-25 years\n\n1b.Type 2 diabetes mellitus as defined by fasting blood glucose \\>= 126 mg\u002FdL OR postprandial blood sugar \\>= 200 mg\u002FdL OR Hemoglobin A1c \\>= 6.5% per American Diabetes Association Criteria and one element from the medical history consistent with ADA or AAP guidelines including: family history of diabetes and obesity, maternal or personal history of gestational diabetes, high-risk race and ethnicity, history of cardiovascular disease, hypertension, dyslipidemia, polycystic ovary syndrome, physical inactivity, other clinical conditions associated with insulin resistance (e.g. severe obesity, acanthosis nigricans, prediabetes), small or large for gestational age birth weight, history of breastfeeding, gestational history of illicit drugs including alcohol, smoking OR documentation of type 2 diabetes diagnosed at \\\u003C=25 years of age with verified medical history (as above).\n\n2\\. Youth with overweight\u002F obesity (Y-OW)\n\n2a. Age 12-25 years\n\n2b. For participants \\\u003C 18 years of age, BMI \\>= 85th percentile (overweight) and \\>= 95th percentile (obesity) for age and sex OR\n\n2c. For participants \\>= 18 years of age, BMI \\>=25\\\u003C30 kg\u002Fm\\^2 (overweight) or \\>=30 kg\u002Fm\\^2 (obesity)\n\n2d. Participants with obesity may have a diagnosis of prediabetes, defined as fasting blood glucose 100-125 mg\u002FdL OR postprandial blood sugar 140-199 mg\u002FdL OR HbA1c 5.7-6.4 percent (either during testing at NIH or as previously documented on outside medical record).\n\n3\\. Healthy control lean participants (Y-Lean)\n\n3a. Age 12-25 years\n\n3b. For participants \\\u003C 18 years of age, BMI \\\u003C= 85th percentile for age and sex OR\n\n3c. For participants \\>=18 years of age, BMI 18-24.99 kg\u002Fm\\^2.\n\n3d. HbA1c \\\u003C5.7 percent (either during testing at NIH or as previously documented on outside medical record).\n\n4\\. Biological parents of Y-T2DM, Y-OW and Y-Lean participants\n\n4a. Biological parent of enrolled Y-T2DM, Y-OW and Y-Lean by self-report.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria for their specific group will be excluded from participation in this study:\n\n1\\. Y-T2DM, Y-OW and Y-Lean Participants:\n\n1a. Type 1 diabetes or the presence of \\>2 diabetes auto-antibodies (e.g., GAD-65, IA-2 antigen, Zinc transporter 8 autoantibodies).\n\n1. b. Medical, psychiatric or cognitive disorders that will, in the opinion of the investigators, limit the subject s ability to comply with study procedures (specific obesity-related comorbidities are explicitly permitted, including hypertension, hyperlipidemia, obstructive sleep apnea and non-alcoholic steatohepatitis).\n\n1c. Serious medical illnesses or diseases thought to alter metabolism (including moderate to severe renal disease (\\\u003C 30 mL\u002Fmin\u002F1.73m\\^2), congenital heart disease, Cushing s syndrome, cancer, or other metabolic diseases associated with diabetes or excess weight).\n\n1d. For participants enrolled at the NIH, dietary allergies, intolerances or eating patterns that would preclude them from consuming metabolic meals.\n\n1e. Unwilling to comply with all study procedures or to adhere to Lifestyle Considerations throughout study duration.\n\n1f. Pregnancy at the time of the screening visit.\n\n1g. Clinically significant anemia OR Hematocrit below the lower limit of normal for age and sex cutoffs.\n\n1. h. For Y-OW Participants- Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above.\n\n2\\. Y-Lean participants:\n\nIn addition to the above exclusion criteria, any Y-Lean participant who meets any of the following additional criteria will be excluded from the study:\n\n2a. Current use of prescription or non-prescription medication. Certain exceptions are permitted, including topical medications, vitamins, and hormonal contraceptives. Other medications may be permitted at the discretion of the investigators.\n\n2b. Recent (past 2 months) use of drugs or supplements that alter glucose or lipid metabolism (e.g., niacin, fish oil, red yeast rice)\n\n2c. History of diabetes or abnormal glucose tolerance\n\n2d.. Abnormal screening labs, including the following:\n\ni) ALT or AST \\>2 times the upper limit of normal\n\nii) Glycosuria\n\niii) Low eGFR (\\\u003C90 mL\u002Fmin\u002F1.73m\\^2)Any other abnormality that, in the opinion of the investigator, will increase risk to the subject from participation, or interfere with interpretation of study data\n\n2e. Meet lab and medical history criteria for Y-T2DM as described in inclusion criterion 1b above.\n\n3\\. Biological Parents\n\n-No Exclusion Criteria","12 Years","25 Years",{"count":108,"type":22},930,"Background:\n\nType 2 diabetes is a disease that affects blood sugar levels. Complications can include heart and blood vessel (vascular) diseases. Rates of type 2 diabetes have tripled in children and young adults over the last 40 years. Vascular diseases are also increasing in young people.\n\nObjective:\n\nTo learn more about factors, including type 2 diabetes, that may cause vascular disease in young people.\n\nEligibility:\n\nPeople aged 12 to 25 years who (1) have type 2 diabetes; (2) are overweight but not diabetic; (3) or are lean and healthy. Biological parents are also needed.\n\nDesign:\n\nYoung participants will visit the NIH clinic once a year for up to 25 years. Each visit will take 4 days. Before each visit, participants will wear devices to track their sleep, activity, and blood sugar levels for 7 to 10 days.\n\nAt each visit, participants will have tests including:\n\nSamples: They will provide blood, urine, and stool samples.\n\nHeart: They will ride a stationary bike for 6 minutes with stickers applied to their chest.\n\nScans: They will lie on a bed that slides into a tube; the machine will take pictures of the inside of their body.\n\nEnergy: They will wear a hood over their head to measure the air they breathe.\n\nSocial stress: They will give a speech for 10 minutes to show their body s response to stress.\n\nGlucose: They will drink a sweet drink to see how their blood sugar changes.\n\nBiological parents will have 1 study visit. They will have blood tests. They will fill in questionnaires about their lifestyle and stress.\n\n...",[28,26],[112,113,28,114,115],"Cardiovascular Disease","Overweight","Youth Onset Type 2 Diabetes","Lean",{"date":92,"type":35},{"date":118,"type":35},"2025-03-12",{"date":120,"type":22},"2033-10-31",{"name":122,"class":123},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",2,{"id":126,"slug":4,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":55,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":43},"100617406","NCT07318207","Time-restricted Eating for Patients With Type 2 Diabetes","A Pragmatic Clinical Trial of Time-restricted Eating in the University of Kentucky Barnstable Brown Diabetes Center","Inclusion Criteria:\n\n* Diagnosis of Type 2 Diabetes\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Diagnosed eating disorder\n* Night shift worker\n* Taking drugs which induce hypoglycemia\n* Unable or unwilling to participate in the time-restricted eating intervention",{"count":132,"type":22},102,[57],"This is a single-arm pragmatic clinical trial of time-restricted eating in patients with type 2 diabetes. Patients will be recruited from the University of Kentucky Barnstable Brown Diabetes Center. Subjects will participate in a 10-hour time-restricted eating intervention for 1-year.",[26],"2026-06-30",{"date":92,"type":35},{"date":139,"type":22},"2026-07",{"date":141,"type":22},"2028-06",{"name":143,"class":42},"Justin (Matt) Thomas",{"id":145,"slug":4,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":55,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":124},"100578660","NCT06814184","Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy","Nurse-led App Intervention to Improve Glycemic Control in Patients With Insulin-treated Type 2 Diabetes on Medicaid","virtual care","Inclusion Criteria:\n\n* A1C \\>7 for age 18-64, A1C\\>8 for age 65 or older within 12 months prior baseline\n* A1C\\>7 for age 18-64, A1c\\>8 for age 65 or older at baseline\n* Medicaid recipient or dual Medicaid and Medicare recipient\n* Age 18 or older\n* Type 2 diabetes\n* On insulin therapy\n* Owning and using Android or iOS smartphone for at least 6 months\n* English proficiency\n* Adequate vision to read text messages on their current smartphone\n* Smartphone use proficiency. Smartphone proficiency will be self-reported and determined by telephone as the ability to use a smartphone in ways other than emailing, texting, and making phone calls.\n\nExclusion Criteria:\n\n* Pregnancy\n* Patients with cognitive impairment who will be screened with the Six-Item Screener to Identify Cognitive Impairment Among Potential Research Subjects.","90 Years",{"count":153,"type":22},60,[57],"This 12-month pilot tests a nurse-led, app-based intervention to improve diabetes self-management for Medicaid patients. It includes MyChart messaging to give education, phone help on problem-solving with clinicians, and using a diabetes app to track data. The study aims to enhance self-management behaviors through health technology.",[26],[158,159,160,161],"diabetes app","behavioral intervention","self-management","diabetes",{"date":92,"type":35},{"date":164,"type":35},"2026-04-01",{"date":166,"type":22},"2028-12-01",{"name":168,"class":42},"Rutgers, The State University of New Jersey",{"id":170,"slug":4,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":176,"maxAge":51,"enrollmentInfo":177,"targetDuration":4,"studyType":55,"phases":179,"briefSummary":180,"conditions":181,"keywords":184,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":43},"100474852","NCT05463289","ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2","Implementing Digital Retinal Exams Into Comprehensive Pediatric Diabetes Care","ACCESS2","Inclusion Criteria:\n\nMeets American Diabetes Association (ADA) criteria for diabetic retinopathy screening:\n\n* Diagnosis of Type 1 diabetes for ≥3 years, and age 11 or in puberty\n* Diagnosis of Type 2 diabetes\n\nEnriched cohort:\n\n* Patients with Type 1 or Type 2 diabetes,\n* 8-21 years of age with known diabetic retinopathy (true positives).\n* No time limit on last diabetic eye exam.\n\nExclusion Criteria:\n\n* Known diabetic eye exam in the last 12 months","8 Years",{"count":178,"type":22},500,[57],"The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy, and to determine the diagnostic accuracy of the autonomous AI system in detecting diabetic retinopathy from retinal images of youth with diabetes.",[182,26,183],"Type 1 Diabetes","Cystic Fibrosis-related Diabetes",[185],"Diabetic Retinopathy",{"date":92,"type":35},{"date":188,"type":35},"2022-07-11",{"date":190,"type":22},"2026-09-30",{"name":192,"class":42},"Johns Hopkins University",{"id":194,"slug":4,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":43},"100410199","NCT04621396","The Next Generation Longitudinal Birth Cohort Diabetes Study","Genetic and Environmental Influences on Development of Type 2 Diabetes in Childhood: The Next Generation Longitudinal Birth Cohort.","NextGen","Inclusion Criteria:\n\n* Pregnant women with type 2 diabetes, gestational diabetes, or no diabetes.\n* From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.).\n* Are delivering and residing in Manitoba.\n* Mother\u002FFather and children must be biological family members.\n\nExclusion Criteria:\n\n* Mothers or children with type 1 diabetes.\n* Residing outside of Manitoba.",{"count":201,"type":22},600,"The overall aim of this project is to understand the independent roles of maternal factors, intrauterine exposures, genetic factors, and postnatal environment on the development of obesity and youth-onset type 2 diabetes (T2D) in childhood.",[26,204],"Gestational Diabetes Mellitus",{"date":92,"type":35},{"date":207,"type":35},"2013-09",{"date":209,"type":22},"2028-12",{"name":211,"class":42},"University of Manitoba",{"id":213,"slug":4,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":218,"maxAge":83,"enrollmentInfo":219,"targetDuration":4,"studyType":55,"phases":220,"briefSummary":223,"conditions":224,"keywords":228,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},"100645002","NCT07675499","Exercise and Intranasal Insulin in Type 2 Diabetes","Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes","Inclusion Criteria:\n\n* Male or female 55-80 years old\n* Type 2 diabetes diagnosis or confirmation HbA1c \\>6.5% and fasting glucose \\>126 mg\u002Fdl\n* Individuals prescribed metformin, GLP-1 agonists (oral\u002Finjectable), TZDs, DPP-IV inhibitors, Acarbose, SGLT-2 inhibitors \\>6 months.\n* MOCA ≥26\n* Body mass index (BMI) ≥25 and ≤40 kg\u002Fm2\n* Not diagnosed with Type 1 diabetes\n* Not currently engaged in \\\u003C90 min\u002Fwk of exercise\n\nExclusion Criteria:\n\n* A diagnosis of dementia\n* Neurologic disease (e.g. Parkinson's, autonomic neuropathy, etc.)\n* Intolerance to insulin\n* Morbidly obese patients (BMI \\>40 kg\u002Fm2) and lean patients (BMI \\\u003C25 kg\u002Fm2)\n* \\>2 kg weight change in past 6 months\n* Participants who have been recently active (\\>90 min of moderate\u002Fhigh intensity exercise)\n* Individuals who are smokers or who have quit smoking (\\\u003C2 years)\n* Hypertriglyceridemia (400 mg\u002Fdl) and hypercholesterolemic (\\>260 mg\u002Fdl) subjects\n* Uncontrolled Hypertensive (\\>160\u002F100 mmHg)\n* Participants with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety\n* Pregnant (as evidenced by positive pregnancy test) or nursing women\n* Participants with contraindications to participation in an exercise training program\n* Major psychiatric disorders (e.g. psychosis, bipolar disorder, major depression, alcohol\u002Fsubstance abuse)\n* History of head trauma or loss of consciousness in last 5 years.\n* Known contraindications for MR imaging:\n\n  * History of head trauma or neurosurgery, or neurological disorder (other than headaches or peripheral nerve disease) as these may impact neuroimaging results.\n  * Ferrous material implanted in or on the body, including flakes or filings, surgical clips, bullets, or electrical devices such as a pacemaker, or nonremovable ferrous jewelry (fillings in teeth and permanent retainers are permitted).\n  * Fillings and permanent retainers do not provide a safety risk and are not general exclusions. However, upper retainers may cause artifacts in ventral frontal regions and therefore may be an exclusion for some studies.\n  * Individuals with surgical pins or plates above the neck are excluded. Surgical pins or plates below the neck are exclusions, except when the material is fixed to bone, and considered acceptable by the Reference Manual for Magnetic Resonance Safety. Implants and Devices, 2020 Edition. Almost all recent orthopedic implants are made of materials that are not ferromagnetic and therefore are safe for scanning, and even though some screws are still made of ferromagnetic materials these are firmly screwed into bone. In cases where the material is unknown or deemed unsafe for scanning by the Reference Manual for Magnetic Resonance Safety. Implants and Devices the participant will be excluded.\n  * History of eye injury involving metallic materials, shavings in eyes, or welding without a face mask\n  * Lead\u002Firon tattoos\n  * Claustrophobia (history of significant anxiety in closed places).\n  * Back problem that would prevent the subject from laying still comfortably for up to 90 minutes.\n  * Deafness","55 Years",{"count":153,"type":22},[221,222],"PHASE2","PHASE3","About 6.5 million adults in the United States who are 65 or older have dementia.\n\nWhile the exact cause of dementia is not known, it may be due to changes in the brain. Further, risk may be higher when the brain does not respond to insulin. Indeed, brain insulin resistance has emerged as a pathologic factor affecting memory, executive function as well as systemic glucose control. Regular aerobic exercise may help reduce the risk of dementia by increased blood flow to the brain and help the brain respond better to insulin. In addition, giving insulin through a nose spray (called intranasal insulin) may also help with thinking and memory. However, it is unknown if using both exercise and intranasal insulin is best for the brain.",[26,225,226,227],"Insulin Sensitivity\u002FResistance","Cognition","Brain Blood Flow",[229,230],"Exericse","Intranasal Insulin","2026-06-26",{"date":136,"type":35},{"date":234,"type":22},"2026-08-03",{"date":236,"type":22},"2029-05-31",{"name":168,"class":42},4,{"id":240,"slug":4,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":17,"minAge":245,"maxAge":51,"enrollmentInfo":246,"targetDuration":4,"studyType":55,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":258,"locationsCount":43},"100635745","NCT07556679","PLAY2CONTROL Study","Active Video Games and Their Effect on Weight Loss and HgbA1c in Patients With Obesity and Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Patients followed at the University of Miami Pediatric Endocrinology Clinic\n* Must have a diagnosis of Obesity (BMI \\>= 95th percentile) and Type 2 Diabetes Mellitus (Hemoglobin A1c \\> 6.5%)\n* Children and teenagers, 5-18 years old\n* Young adults 19-21 years old\n\nExclusion Criteria:\n\n* Patients who have conditions preventing physical activity (such as physical limitations)\n* Patients without Televisions at home\n* Pregnant females\n* Patients in juvenile detention or prison\n* Adults unable to consent","5 Years",{"count":247,"type":22},30,[57],"The purpose of this study is to assess the impact of active video gaming participation in otherwise sedentary patients with obesity and Type 2 diabetes mellitus. The study will assess changes in sedentary time, activity level and changes in weight and Hemoglobin A1c, as well as other complications related to obesity that is monitored in clinic.",[26,251],"Obesity & Overweight",[253],"Pediatrics",{"date":90,"type":35},{"date":71,"type":22},{"date":257,"type":22},"2027-08",{"name":259,"class":42},"University of Miami",{"id":261,"slug":4,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":55,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":43},"100524940","NCT06115265","Ketogenic Diet and Diabetes Demonstration Project","KDDP","Inclusion Criteria:\n\n* Men and women ≥ 18 years old\n* BMI ≥27 kg\u002Fm2\n* Hemoglobin A1c ≥ 5.7% and\u002For fasting plasma glucose of 100-125 mg\u002FdL\n\nExclusion Criteria:\n\n* Known clinical cardiovascular disease (i.e. prior stroke, myocardial infarction, peripheral artery disease)\n* LDL cholesterol ≥ 190 mg\u002FdL\n* Triglycerides ≥ 500 mg\u002FdL\n* History of type 1 diabetes\n* History of diabetic ketoacidosis\n* Individuals requiring insulin\n* Advanced renal disease\n* Advanced liver disease\n* Terminal cancer\n* Pregnancy",{"count":54,"type":22},[57],"KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that participants in KDDP will be placed on a medically-supervised ketogenic diet, and participants in NDPP will be placed on a low fat diet.\n\nThe purpose of this study is to compare the metabolic effects of the KDDP and the NDPP on glycemic control, lipid parameters, blood pressure, heart rate, weight, and coronary artery calcium scores in individuals with either type 2 diabetes or prediabetes.",[26,30,28,270],"Ketogenic Dieting",{"date":136,"type":35},{"date":273,"type":35},"2023-09-05",{"date":275,"type":22},"2026-10-01",{"name":277,"class":42},"University of New Mexico",{"id":279,"slug":4,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":55,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":43},"100378899","NCT04213547","Sleep and Glycemic Control in Type 2 Diabetes Adolescents","Sleep Duration and Glycemic Control in Adolescents With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\nAim 1 for child:\n\n1. Subjects age 12-20\n2. Diagnosed with T2DM by standard laboratory criteria without pancreatic autoimmunity\n3. Low probability of obstructive sleep apnea (OSA) assessed via validated sleep survey\n4. Subjects will be included if they are taking T2DM treatments (i.e., diet modification, Metformin and\u002For insulin)\n5. Parental\u002Fguardian permission and child assent\n\nAim 1 for parent:\n\n1\\. Parent or legal guardian of child that meets inclusion criteria for Aim 1.\n\nAim 2 for child:\n\n1. Completed Aim 1 evaluation\n2. Average sleep duration \\\u003C 8 hours per night as determined by actigraphy in Aim 1\n3. HbA1c ≤ 10% as HbA1c \\>10 correlates to poor adherence\n4. Adherence \\> 80%\n\nFocus group for child:\n\n1. Subjects aged 12-20\n2. Diagnosed with type 2 diabetes without pancreatic autoimmunity\n\nExclusion Criteria:\n\nAim 1 for child:\n\n1. Non-English speaking subject (as questionnaires used are validated in English)\n2. Institutionalized patients as sleep duration will not be of their own accord, and therefore is not generalizable to the rest of the adolescent T2DM population.\n3. Patients with other forms of Diabetes Mellitus (e.g. Type 1 Diabetes)\n4. Behavioral disorders that may affect data collection (e.g. autism spectrum disorder) will be determined on a case-by-case basis. These include patients that are unable to answer questionnaires on their own, participate in a sleep diary, wear devices and\u002For understand incentives.\n5. Oral or IV steroid treatment within the past month\n6. Females with known pregnancies as these patients will not be generalizable to the rest of the adolescent T2DM population and pregnancy may alter sleep duration.\n7. Subjects with known hyperthyroidism, pain syndrome, or serious medical condition that can affect sleep.\n8. Subjects with hemoglobinopathies that affect hemoglobin A1c measurement.\n9. Unable to obtain point-of-care hemoglobin A1c in clinic on date of recruitment\n10. Known diagnosis of obstructive sleep apnea or other sleep disorder\n\nAim 1 for Parent:\n\n1. Non-English speaking subject (as questionnaires used are validated in English)\n2. Parent\u002Fguardians with cognitive disorders that may affect data collection (determined on a case-by-case basis)\n\nAim 2 for child:\n\n1\\. Do not own a smart phone or tablet\n\nFocus group for child:\n\n1. Non-English speaking subject (as focus group will be conducted in English)\n2. Lack of access to a computer, tablet or smartphone that can accommodate participation in video conferencing","20 Years",{"count":286,"type":22},90,[57],"The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can increase sleep duration in 15 adolescent patients diagnosed with T2DM with insufficient sleep. Another secondary objective is to test if increasing sleep duration leads to improved glycemic control in 15 adolescents with T2DM identified in Aim 1 as having \\\u003C8 hr sleep\u002Fevening. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.",[26],"2026-06-25",{"date":292,"type":35},"2026-06-29",{"date":294,"type":35},"2020-09-16",{"date":296,"type":22},"2028-07-01",{"name":298,"class":42},"Children's Hospital of Philadelphia",{"id":300,"slug":4,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":305,"maxAge":19,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":43},"100271830","NCT02818192","Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)","iCARE","Inclusion Criteria:\n\n* All youth with T2D that do not meet exclusion criteria are eligible for the study.\n\nCriteria for Diagnosis of T2D:\n\n1. Diagnosis of diabetes will be made according to the Canadian Diabetes Association criteria. There must be 2 abnormal blood glucose tests on different days OR 1 abnormal blood glucose test + symptoms of diabetes:\n\n   * Fasting plasma glucose of \\> 7.0 mmol\u002FL or\n   * Random glucose \\> 11.1mmol\u002FL or\n   * 2 hour glucose \\> 11.1 mmol\u002FL after a standard oral glucose tolerance test (75g) or\n   * Hemoglobin A1c value ≥ 6.5%\n2. Distinguishing T2D from type 1 diabetes (T1D) will be based on clinical risk factors including:\n\n   * Presence of overweight\u002Fobesity,\n   * Other evidence of insulin resistance (acanthosis nigricans)\n   * Family history of type 2 diabetes (1st degree relative)\n   * Intrauterine exposure to hyperglycemia,\n   * Family heritage from a high-risk ethnic group (Indigenous, Hispanic, South Asian, Asian or African descent)\n   * Absence of diabetes associated auto-antibodies\n   * HNF-1 alpha heterozygote or homozygote\n\nExclusion Criteria:\n\n1. Diabetes secondary to medication use or surgery\n2. Antibodies suggestive of type 1 diabetes\n3. Current treatment with oral steroids or immunosuppressive agents as they may interfere with cortisol assessment and inflammatory markers\n4. Ever cancer\n5. Other chronic illness associated with systemic inflammation (ex. Juvenile rheumatoid arthritis, Crohns disease)\n6. Patient and or caregiver unable or unwilling to provide voluntary informed assent\u002Fconsent","10 Years",{"count":178,"type":22},"The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include:\n\n1. Characterize the primary BPS risk factors associated with prevalent and progressive albuminuria in youth with T2D.\n2. Determine individual, family and community level factors that influence biological and psychological risk factors and behaviors (adherence) that could be modified to protect against prevalent and progressive albuminuria.\n3. Determine if systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.\n\nStudy Hypotheses include:\n\n1. Biological factors (poor glycemic control and systolic ambulatory hypertension), and psychological and social adversity (stress, mental distress and poverty) are significant predictors of prevalent and progressive albuminuria in youth with T2D.\n2. Community and family support will be negatively associated with stress, and a lower risk of both prevalent and progressive albuminuria.\n3. Systemic and renal inflammation is the common pathway through which BPS risk factors lead to albuminuria in youth with T2D.",[26,309,310,311],"Proteinuria","Stress","Nephropathy",{"date":292,"type":35},{"date":314,"type":35},"2017-01",{"date":316,"type":22},"2027-03",{"name":211,"class":42},{"id":319,"slug":4,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":17,"minAge":324,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":55,"phases":327,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":4},"100645074","NCT07677891","Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus","A Randomized, Open-Label, Multicenter, Active-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Switching From Once-Weekly Dulaglutide to Once-Monthly PG-102(MG12) in Patients With Type 2 Diabetes Mellitus Receiving Stable Dulaglutide Therapy","Inclusion Criteria:\n\n1. Adults aged 19 to 75 years who provide informed consent.\n2. Diagnosed with type 2 diabetes for at least 6 months prior to screening.\n3. Stable on dulaglutide therapy (0.75 or 1.5 mg) for at least 12 weeks prior to screening, with dose and dosing interval maintained unchanged for 8 weeks prior to enrollment.\n4. HbA1c ≤ 7.5% at screening.\n5. If receiving oral anti-diabetic drugs (OADs), on a stable dose for at least 90 days prior to screening.\n6. BMI between 18.5 kg\u002Fm² and 30.0 kg\u002Fm².\n\nExclusion Criteria:\n\n1. Received any investigational medicinal product within 30 days prior to screening, or within 5 half-lives of the product if known (whichever is longer).\n2. History of hypersensitivity or severe adverse reactions to GLP-1RA, GLP-2 agents, the investigational product, or its components.\n3. Type 1 diabetes, special forms of diabetes (e.g., monogenic, post-pancreatectomy, steroid-induced), or history of DKA or HHS within 6 months prior to screening\n4. Severe gastrointestinal disorders affecting gastric emptying (e.g., gastroparesis, inflammatory bowel disease, gastric\u002Fduodenal ulcer, intestinal obstruction) or history of related surgery within the past year (e.g., sleeve gastrectomy, biliopancreatic diversion, jejunal\u002Fileal bypass).\n5. Uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥110 mmHg) or severe hypertriglyceridemia (fasting triglycerides ≥500 mg\u002FdL) despite appropriate treatment. Patients may be enrolled if these conditions are adequately controlled during screening.\n6. NYHA Class III or IV heart failure; acute coronary syndrome (including MI), unstable angina, clinically significant CAD (CCS Class III-IV), CABG or emergent PCI, TIA, or cerebrovascular accident within the past 6 months. Patients may be enrolled if the event occurred \\>6 months ago and is considered resolved or stable.\n7. Active pancreatitis, history of recurrent or severe pancreatitis, or clinically significant gallbladder disease (e.g., cholecystitis, complications from gallstones) that is unresolved or at risk of recurrence.\n8. Active malignancy or history of malignancy treatment within the past 5 years. Exceptions: completely cured basal cell carcinoma, cervical carcinoma in situ, or other cured malignancies with no risk of recurrence as judged by the investigator.\n9. Personal or family history (first-degree relatives) of MEN type 2 or thyroid C-cell carcinoma (e.g., MTC). Exception: surgically cured simple thyroid nodules or benign non-C-cell thyroid conditions (e.g., thyroid adenoma, thyroid dysfunction).\n10. Active infectious disease (e.g., active TB, active viral hepatitis, HIV), or confirmed HBsAg-positive, HCV RNA-positive, or HIV infection, unless documented to be completely cured or currently inactive.\n11. History of hospitalization or emergency treatment for moderate or severe depressive disorder, bipolar disorder, or schizophrenia spectrum disorder within the past year. Exception: patients whose symptoms are currently stable under appropriate treatment and deemed safe to participate as assessed by the investigator.\n12. Therapeutic use of systemic corticosteroids for more than 14 days within 90 days prior to screening. Exception: short-term use (≤10 days) or non-absorbable topical, inhaled, intra-articular, or dermatological formulations.\n13. Diagnosis of or clinically suspected alcohol or drug abuse or dependence within 90 days prior to screening.\n14. AST or ALT \\>3× ULN or total bilirubin \\>2× ULN at screening. Exception: transient elevations confirmed to have normalized or to be stable on repeat testing.\n15. Estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002Fmin\u002F1.73 m² calculated by CKD-EPI equation.\n16. Moderate or severe hepatic impairment (Child-Pugh Grade B or above) or currently active drug-induced liver disease. Exception: history of drug-induced liver disease with complete recovery and stable liver function tests (AST, ALT, total bilirubin) within normal range.\n\n\"17. Severe or active diabetic complications, including:\n\n* Proliferative diabetic retinopathy currently receiving or requiring treatment (laser, vitrectomy, anti-VEGF, or steroid injections) within the past 3 months or planned treatment. (Non-proliferative or stable retinopathy is permitted with fundus examination at screening and regular follow-up.)\n* Diabetic nephropathy with overt proteinuria (≥300 mg\u002Fday) or eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m²\n* Severe diabetic neuropathy with uncontrolled pain despite optimized pharmacotherapy (e.g., antidepressants, gabapentinoids, analgesics) for ≥3 months, requiring continuous use of opioid or multiple combination analgesics.\n* Exception: patients with past complications that are currently stable and deemed safe to participate as assessed by the investigator.\" 18. Fertile women or fertile men (including those with fertile female partners) who do not agree to use dual contraception or abstinence from the time of written consent until 90 days after the last dose of investigational product. (Fertile women must have a negative serum pregnancy test during screening prior to study entry).\n\n  19\\. Currently pregnant or breastfeeding, or planning pregnancy during the study period or within 90 days after the last dose of investigational product.\n\n  20\\. Previous experience of persistent or recurrent vomiting or severe diarrhea requiring hospitalization, emergency treatment, or drug discontinuation following GLP-1 receptor agonist or GLP-2 analogue administration, or history of intestinal obstruction.\n\n  21\\. Patients who required dose reduction of dulaglutide due to intolerance and subsequently failed re-escalation to the previous dose. Exception: patients assessed by the investigator as currently maintaining stable treatment at the reduced dose.\n\n  22\\. History of or planned use of prohibited concomitant medications within 90 days prior to screening or during the study period. Exception: short-term use (≤14 days) for therapeutic necessity with no anticipated pharmacokinetic or pharmacodynamic interaction with the investigational product as judged by the investigator.\n\n  23\\. Use of insulin for diabetes management during the 1 year prior to screening. Exception: acute short-term use (≤14 days) during hospitalization or perioperative periods.\n\n  24\\. Patients deemed inappropriate for study participation by the investigator based on safety, compliance, or medical judgment (considering physical examination, baseline test results, medical history, etc.).\n\n  25\\. Self-reported body weight change of \\>5% within 12 weeks (90 days) prior to screening.\n\n  26\\. History of untreatable colorectal polyps. 27. Presence of factors that may affect IGF-1 measurement, such as growth hormone (GH) injections.","19 Years","75 Years",{"count":153,"type":22},[221],"This is a randomized, open-label, multi-center, active-controlled Phase 2 clinical trial to evaluate the efficacy and safety of switching from once-weekly dulaglutide to PG-102(MG12) in patients with type 2 diabetes mellitus receiving stable dulaglutide therapy.\n\nThe treatment period is 32 weeks, with an additional 4-week safety follow-up. The primary endpoint is the change in HbA1c(%) from baseline at Week 32.",[26],[331,332,26,333],"PG-102","ProGen","GLP-1\u002FGLP-2","2026-06-24",{"date":90,"type":35},{"date":337,"type":22},"2026-10",{"date":339,"type":22},"2027-06",{"name":341,"class":42},"ProGen. Co., Ltd.",{"id":343,"slug":4,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":55,"phases":351,"briefSummary":352,"conditions":353,"keywords":354,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":358,"leadSponsor":359,"locationsCount":43},"100644841","NCT07674979","Cardiometabolic Impact of a Produce Prescription Program in Patients With Type 2 Diabetes and Food Insecurity","A Randomized Crossover Trial Evaluating the Cardiometabolic Impact of a Produce Prescription Program in Patients With Type 2 Diabetes and Food Insecurity","GARDEN-CARDIO","Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus\n* Most recent HbA1c \\>8% within the prior 6 months\n* Must have had a clinic visit within the past 6 months\n* Positive screening for food insecurity based on the USDA 6-item food security survey\n* Receiving care through WVU cardiometabolic, endocrinology, or primary care clinics\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* End-stage renal disease\n* Advanced heart failure\n* Severe cognitive impairment\n* Chronic pancreatitis\n* Pancreatic malignancy\n* Pregnancy at time of enrollment\n* Anticipated inability to utilize intervention vouchers (e.g., lack of access to Walmart)",{"count":350,"type":22},88,[57],"This study is testing whether providing monthly vouchers to buy fruits and vegetables can help improve blood sugar control in adults with type 2 diabetes. People receiving care at WVU clinics who recently had an HbA1c level above 8% will be invited to participate in the study. Those who are interested will speak with a study coordinator, be screened for eligibility, and, if eligible, will provide written consent to join the study. Participants will be randomly assigned to one of two groups. One group will receive $100 per month in produce-only grocery vouchers and standardized dietary education for 5 months, followed by 5 months of usual diabetes care. The second group will receive usual diabetes care first for 5 months, followed by 5 months of produce-only grocery vouchers and standardized dietary education. This crossover design allows all participants to experience both approaches during the study. Researchers will measure changes in blood sugar (HbA1c) as the main outcome. Other outcomes include blood pressure, cholesterol levels, body weight, diet quality, food security, anxiety symptoms, depressive symptoms, and physical activity. These will be assessed through lab tests, clinic measurements, and surveys at certain time points during the 10 month study period. The study team will also track how often participants use the vouchers and any challenges they face. The risks of participating are expected to be minimal and similar to routine diabetes care. The total study duration, including enrollment, participation, and analysis, is expected to be about 18 months.",[26],[355],"Food Insecurity",{"date":136,"type":35},{"date":139,"type":22},{"date":339,"type":22},{"name":360,"class":42},"West Virginia University",{"id":362,"slug":4,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":55,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":43},"100589852","NCT06959797","Insulin Pump Versus Full Closed-loop for Type 2 Diabetes","Randomized Cross-over Study Comparing Insulin Pump Versus Full Closed-loop Automated Insulin Therapy in Type 2 Diabetic Patients Previously Treated With Insulin Pumps","IA-DT2","Inclusion Criteria:\n\n* Age \\> 18\n* Type 2 diabetes for at least 12 months\n* On insulin pump for at least 6 months, without\u002Fwith adjuvant treatment exclusively with GLP1-Ra, iSGLT2, metformin for at least 3 months\n* Autonomy in the management of the pump and the glucose sensor\n* HbA1c ≥ 7.5% and \\\u003C 12\n* Participant's agreement to wear and use the Ypsomed with the CamAPS HX algorithm and Free Style Libre 3 sensor, and to honor the study visit schedule\n* For women of childbearing age, effective contraception is required (estrogen-progestin pill, IUD, implant).\n\nExclusion Criteria:\n\n* Type 1 diabetes or monogenic diabetes\n* Use of U500 or U200 insulin concentrate in the pump in the last 3 months\n* Allergy to insulin or to the adhesives used\n* Severe insulin resistance defined by a daily insulin requirement of more than 1.5 U\u002Fkg\n* History of severe hypoglycemia \\> 1 time in the last 6 months.\n* Current or planned use of steroids (oral, injectable) or any treatment likely to have an impact on blood glucose levels within the last 30 days.\n* Current or planned pregnancy, breastfeeding\n* Severe renal failure defined as GFR \\\u003C 30 ml\u002Fmn\n* Proliferative retinopathy or severe maculopathy with risk of worsening during the study\n* Vision or hearing problems that could compromise safe use of the device\n* Acute vascular event within the last 3 months\n* No autonomy for pump treatment\n* Alcohol or substance abuse\n* Legal protection (guardianship, curatorship)\n* Any somatic or psychological condition compromising participation in the study\n* Participation in another clinical trial",{"count":369,"type":22},80,[57],"The aim of the study is to compare, in a population of patients with type 2 diabetes, open-loop insulin pump treatment with the CamAPS HX (Camdiab) Fully Closed Loop Automated Insulin Therapy system, on the efficacy and safety of use of the Fully Closed Loop, as well as on psycho-social criteria of device acceptability, quality of life and diabetes burden. This is an open, multi-center, randomized, cross-over study, based on several observational or controlled trials carried out in Cambridge by Prof. Hovorka's team (see paragraph 4 below). The study will comprise a run-in phase followed by a 1st sequence in which randomized patients will use the Ypsomed pump (Ypsomed) and the FreeStyle Libre 3 sensor in open loop for 12 weeks Versus the Ypsomed pump (Ypsomed) coupled with the CamAPS HX algorithm and the FreeStyle Libre 3 sensor in full closed loop. At the end of this 1ère sequence, all patients will undergo a 2-4 week washout, during which they will use the Ypsomed pump and the FreeStyle Libre 3 sensor in open loop, and then in the 2nd sequence of the study, patients will switch to the other treatment for a further 12 weeks. A total of 80 patients on insulin pumps for at least 6 months will be recruited from 9 French centers. All patients will receive training in the use of the Ypsomed pump, the FreeStyle Libre 3 sensor and the CamAPS HX algorithm. The primary objective is Time on Target 70-180 mg\u002Fdl of 24h measured during the 12 weeks of each therapeutic period. Secondary objectives will be Time in Target 70-180 mg\u002Fdl day and night, Time above Target \\> 180 mg\u002Fdl and \\> 250 mg\u002Fdl, Time below Target \\\u003C 70 mg\u002Fdl and \\\u003C 54 mg\u002Fdl, time in the narrow target range 70-140 mg\u002FdL, mean 24h blood glucose and glycemic variability measured over the 12 weeks of each treatment sequence, HbA1c, weight, total insulin dose and psychosocial endpoints assessed at the start and end of each treatment sequence. Safety data studied will include diabetes-related adverse events (ketoacidosis, symptomatic and severe hypoglycemia) and medical device-related adverse events (pump and sensor).",[26],[374],"Type 2 diabetes, automated insulin therapy",{"date":231,"type":35},{"date":377,"type":35},"2025-05-05",{"date":379,"type":22},"2028-12-31",{"name":381,"class":42},"University Hospital, Caen",{"id":383,"slug":4,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":17,"minAge":324,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":55,"phases":391,"briefSummary":392,"conditions":393,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":43},"100645039","NCT07676305","6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics","Impact of 6-Weeks of Blood Flow Restriction Training on Immune Cell Function and Bioenergetics in Adults withT2D","Inclusion Criteria:\n\nA. Aged 19-64 years. B. Diagnosed with type 2 diabetes with current HbA1c 5.7-9.0% C. Completing \\\u003C150 minutes of moderate-vigorous physical activity per week.\n\nExclusion Criteria:\n\nA. Chronic musculoskeletal condition or recent (within 2 years) cardiovascular event preventing participation in exercise.\n\nB. Unstable type 2 diabetes medication of the last 3 months C. Absolute contraindications to BFR (i.e., peripheral vascular disease) D. A self-reported diagnosis of low iron concentrations, anemia, or being treated for these conditions E. A diagnosis of any red blood cell-altering condition (i.e., sickle cell anemia, poikilocytosis) F. Currently living with any cardiovascular disease, which would impact the ability to participate in exercise safely G. Currently prescribed any medication which would impact the ability to use a heart rate monitor to accurately track intensity","64 Years",{"count":390,"type":22},20,[57],"To conduct a randomized control trial to determine the impact of 6-weeks of blood flow restriction training on immune cell function and bioenergetics in adults living with type 2 diabetes.",[26],"2026-06-23",{"date":136,"type":35},{"date":397,"type":35},"2026-02-11",{"date":399,"type":22},"2027-12-31",{"name":401,"class":42},"University of British Columbia",{"id":403,"slug":4,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":52,"enrollmentInfo":409,"targetDuration":4,"studyType":55,"phases":411,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":4},"100644678","NCT07674628","Supporting Access for Latinx Underserved in Diabetes Management (SALUD-M): Acceptance Based Coping Skills for Hispanic\u002FLatinx Military Patients With Type 2 Diabetes","Supporting Access for Latinx Underserved in Diabetes Management (SALUD-M): An Equity-Driven Study of Acceptance Based Coping Skills for Hispanic\u002FLatinx Military Patients With Type 2 Diabetes Mellitus","SALUD-M","Inclusion Criteria:\n\n(a) Patients ages 18-70, (b) diagnosis of T2DM, (c) current HbA1c (drawn within 6 months) of 7.5% or greater (may be taking oral agents or injectables for diabetes control), (d) evidence of avoidance coping (score \\\u003C48.4 \\[published mean\\] on the Acceptance and Action Diabetes Questionnaire16) or poor self-management skills (score \\\u003C published mean on 2+ subscales of the Summary of Diabetes Self-Care, Activities37), (e) self-described as Hispanic\u002FLatino\u002FLatina\u002FLatinx, (f) preferred language of English or Spanish, (g) receiving care at the study site clinic.\n\nExclusion Criteria:\n\n(a) End-stage renal disease (on dialysis), (b) a medical condition or life circumstance that would contraindicate participation, (c) proliferative diabetic retinopathy precluding participation, (d) inability to read\u002Fcomprehend the informed consent process or study instructions, (e) pregnant or planning to become pregnant in the next 6 months.",{"count":410,"type":22},100,[57],"People of Hispanic or Latino\u002Fa\u002Fx (\"H\u002FL\") ethnicity, including US military servicemembers, Veterans, and their families, experience a higher prevalence of type 2 diabetes and more challenges managing diabetes than non-Hispanic White populations. Uncontrolled diabetes is linked with lower quality of life, diabetes-related emotional distress, and severe medical problems. There are many reasons for this difference, including lack of culturally appropriate and bilingual Spanish healthcare services. Additionally, military patients may have additional barrier accessing behavioral health care, which an important part of treatment for many people with diabetes, such as stigma and unique schedule challenges.\n\nTherefore, this study aims to overcome these barriers and improve healthcare and health outcomes for H\u002FL military patients. We will test a values-based behavior change program, delivered using video telehealth by a bilingual English-Spanish language health coach. The 10-week Acceptance Based Coping (ABaCo) skills program includes 7 virtually-delivered lessons and was developed by the study team in partnership with civilian community health workers and patients. This study will test the helpfulness of ABaCo delivered by a health coach fluent in English and Spanish to military H\u002FL patients. This randomized controlled trial will examine changes in physical and mental health over 6 months for those who receive ABaCo, compared to those who receive usual healthcare. This project will also identify steps for implementing the ABaCo program in other military treatment facilities.\n\nThe ultimate goal of this study is to establish a helpful, easy-to-access, widely available program for H\u002FL military patients with type 2 diabetes that improves quality of life and blood sugar control, and lowers distress about diabetes. This study will also identify best approaches to providing ABaCo in military treatment facilities, providing lessons learned to other large healthcare systems.",[26],[415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433],"type 2 diabetes","acceptance","Latino","Hispanic","Latinx","military","health coach","paraprofessional","virtual","telehealth","acceptance and committment therapy","diabetes distress","blood glucose","HbA1c","veteran","military treatment facility","randomized controlled trial","quality of life","values",{"date":292,"type":35},{"date":436,"type":22},"2026-06-15",{"date":438,"type":22},"2027-06-30",{"name":440,"class":42},"Baylor College of Medicine",{"id":442,"slug":4,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":16,"sex":17,"minAge":447,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":55,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":43},"100642231","NCT07659535","Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on the Prevention of Type 2 Diabetes","Personalized Study With the Lifestyle Tool","Inclusion criteria\n\n* Informed consent\n* Age above 35 years\n* Access to Internet and mobile or computer device\n\nExclusion criteria\n\n* diabetes mellitus\n* conditions or treatments that in the judgement of the Investigator could affect the study evaluation\n* connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.\n* living outside of Sweden\n* inability to read and write in Swedish","35 Years",{"count":449,"type":22},40000,[57],"The overall aim of the study is to investigate the incidence of type 2 diabetes in individuals who have access to a digital intervention tool as compared with randomized controls during three years. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. Users get access to expert-written information about relevant health topics and interact with an LLM to promote reflection on the information.",[26],"2026-06-22",{"date":290,"type":35},{"date":436,"type":22},{"date":457,"type":22},"2030-12-31",{"name":459,"class":42},"Region Skane",{"id":461,"slug":4,"hasResults":11,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":55,"phases":467,"briefSummary":468,"conditions":469,"keywords":471,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":43},"100580375","NCT06836479","Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes","Validation of NOURISH Project's Culturally Tailored Meals on Postprandial Glycemic Response Using Continuous Glucose Monitoring: A Quantitative and Qualitative Study","Inclusion Criteria:\n\n* Self-identification as Asian Indian or Filipino\n* Diagnosed with T2DM\n* Can pick up meals from a designated area on the Stanford Campus\n* Willing to wear a CGM for 30 days\n\nExclusion Criteria:\n\n* Currently taking insulin, GLP -1 and SGLT 2\n* Known severe allergic reactions and\u002For food intolerances that would interfere with the ability to eat\n* Those who, in the opinion of the investigators, cannot reliably complete the study protocol.",{"count":247,"type":22},[57],"The investigators are hoping to determine whether tailoring the diet of someone with type 2 diabetes to their ethnic group while following American Diabetes Association guidelines can make a significant difference in their blood sugar controls. Participants will be required to wear a Continuous Glucose Monitor (CGM) for 1-month so that the investigators can compare blood sugar levels when participants are eating their routine diet vs. the culturally tailored diabetes diet.",[470,26],"Type 2 Diabetes Mellitus (T2DM)",[26,472,473,474,475,476,477,64,478,479,480],"Asian American","Asian Indian","Filipino","Medically Tailored Meals","Culture","Culturally Tailored Meals","Nutritional Interventions","Dietary Adherence","Diabetes Management",{"date":334,"type":35},{"date":483,"type":35},"2026-01-08",{"date":485,"type":22},"2026-11",{"name":487,"class":42},"Stanford University",{"id":489,"slug":4,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":16,"sex":494,"minAge":19,"maxAge":218,"enrollmentInfo":495,"targetDuration":4,"studyType":55,"phases":496,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":43},"100554983","NCT06506175","A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants","A Phase I Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Ability to understand the trial procedures, be able and willing to provide a written informed consent.\n2. Male subject aged 18-55 years (both inclusive) at the time of signing informed consent.\n3. Body weight ≥ 50.0 kg, body mass index (BMI) of 23.0-35.0 kg\u002Fm\\^2 (both inclusive) at screening.\n4. Weight change does not exceed 5 kg within 3 months before screening.\n5. Good general health as judged by the investigator, based on medical history, physical examination, vital signs, clinical laboratory and electrocardiogram (ECG).\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity to trial product(s) or related products.\n2. With previous major organ diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, are judged by researchers to be unsuitable for the study.\n3. Abnormal and clinically significant blood pressure at screening.\n4. History of significant gastrointestinal diseases or related symptoms (e.g., nausea, vomiting, heartburn, or diarrhea), conditions affecting gastric emptying (e.g., pyloric stenosis), or previous gastrointestinal surgery (excluding polypectomy and appendectomy), or acute diarrhea or constipation within 7 days before randomization.\n5. Blood donation within 1 month prior to screening, or blood donation ≥ 400 mL or blood loss ≥ 400 mL within 3 months prior to screening.\n6. Presence of any clinically significant results in examination at screening visit.\n7. Hepatitis B surface antigen (HBsAg), HIV antibody detection, treponema pallidum specific antibody detection, hepatitis C virus antibody (HCVAb) positive.\n8. Presence of - clinically significant ECG results.\n9. Known or suspected history of drug abuse or drug abuse, or urine drug screening test during the screening periodThose who are positive.\n10. Addiction to tobacco and alcohol.\n11. Individuals with special dietary habits deemed unsuitable for participation by the investigator, or those unable to adhere to the dietary requirements of the trial during the study period.\n12. In the opinion of the investigator, there are any other conditions that interfere with the evaluation of the results of the trial or are not suitable for participation of this study.","MALE",{"count":410,"type":22},[497],"PHASE1","The study is being conducted to evaluate the effects of different dosage regimen on the pharmacokinetics of HRS9531 tablets in healthy subjects.",[500,26],"Weight Management",{"date":334,"type":35},{"date":139,"type":22},{"date":504,"type":22},"2026-09",{"name":506,"class":507},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",{"id":509,"slug":4,"hasResults":11,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":55,"phases":514,"briefSummary":515,"conditions":516,"keywords":520,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":525,"leadSponsor":527,"locationsCount":43},"100644010","NCT07668219","Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease.","4.2.1 Inclusion Criteria\n\n* Age over 18 years\n* Chronic kidney disease defined as a glomerular filtration rate (GFR) of less than 60 ml\u002Fmin\u002F1.73 m², in at least two measurements within the six months prior to inclusion.\n* Treatment with basal insulin, basal-bolus regimen, or co-formulation with or without oral antidiabetic agents, with or without a GLP-1 analogue, with stable treatment for the last 3 months.\n\n4.2.2 Exclusion Criteria\n\n* Type 1 diabetes.\n* Severe cognitive impairment or dysfunction that prevents device management.\n* Chronic kidney disease on renal replacement therapy (peritoneal dialysis or hemodialysis).\n* Patients with a history of kidney transplantation.",{"count":247,"type":22},[57],"* Rationale: Glucose control in patients with kidney disease is challenging, as traditional metrics can be unreliable and there is a high risk of hypoglycemia (low blood sugar). Although RT-CGM has shown benefits in other groups, its efficacy in patients with advanced kidney damage needs to be validated to improve their quality of life and prevent disease progression.\n* Main objective: To determine whether the use of RT-CGM is more effective than usual care (capillary blood glucose monitoring with a glucometer) in maintaining patients within an optimal glucose range (70-180 mg\u002FdL) over a three-month period.\n* Study population: We plan to include 30 patients over 18 years of age with type 2 diabetes and chronic kidney disease (with a glomerular filtration rate less than 60 ml\u002Fmin), who use insulin and are not on renal replacement therapy such as dialysis.\n* Methodology: The study is a randomized clinical trial consisting of two phases:\n\n  1. Selection period (15 days): Blinded monitoring is performed to obtain baseline data.\n  2. Treatment period (90 days): Patients are divided into two groups: the intervention group, which will use the CGM-RT with alarms configured for high and low levels, and the control group, which will continue with traditional fingerstick monitoring.\n* Metrics to be evaluated: In addition to time in range, researchers will analyze episodes of hypoglycemia and hyperglycemia, glycemic variability, glycated hemoglobin (HbA1c) levels, and device accuracy.\n* Ethical and logistical considerations: The study complies with international and national regulations, guaranteeing the confidentiality and autonomy of the participants. The project has a 24-month timeline and a detailed budget to cover medical personnel, monitoring sensors (Sinocare i3), and laboratory tests.",[26,517,518,519],"Kidney Disease","CGM","Time in Range",[26,517,64,521],"Time in range","2026-06-19",{"date":290,"type":35},{"date":485,"type":22},{"date":526,"type":22},"2027-05-30",{"name":528,"class":42},"Hospital Universitario San Ignacio",{"id":530,"slug":4,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":325,"enrollmentInfo":535,"targetDuration":4,"studyType":55,"phases":537,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":153},"100585062","NCT06897475","A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide","A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal","Inclusion Criteria:\n\n* Have type 2 diabetes\n* Have HbA1c ≥7.5% to ≤10.5% at screening\n* Have a body mass index (BMI) of ≥27 kilograms per square meter (kg\u002Fm2) at screening\n* Have had a stable body weight for the three months prior to screening\n* On stable treatment dose of one of the following incretins for at least three months prior to screening:\n\n  * Injectable semaglutide (1 and 2 milligram (mg))\n  * Injectable tirzepatide (5, 7.5, 10, 12.5 and 15 mg)\n\nExclusion Criteria:\n\n* Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar coma\n* Have a prior or planned surgical treatment for obesity\n* Have any of the following cardiovascular conditions within three months prior to screening:\n\n  * acute myocardial infarction\n  * cerebrovascular accident (stroke)\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have used insulin to control blood glucose within the past year (short-term use allowed)\n* Current use of prohibited oral antihyperglycemic medication (OAM) (including but not limited to, Dipeptidyl Peptidase IV Inhibitors (DPP-4i) and meglitinides) may be randomized if the prohibited OAM treatment was discontinued at least 3 months prior to screening\n\n  * If participant has been on stable doses (for at least three months) of up to three permitted OAMs (limited to metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, alpha-glucosidase inhibitors, sulfonylurea, and\u002For thiazolidinediones (TZD), they are permitted to participate in the study\n* Have taken any medications or alternative remedies for weight loss within three months prior to screening",{"count":536,"type":22},240,[221],"The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.",[26],[28,113],{"date":394,"type":35},{"date":543,"type":35},"2025-03-28",{"date":545,"type":22},"2027-01",{"name":547,"class":507},"Eli Lilly and Company",{"id":549,"slug":4,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":11,"sex":554,"minAge":19,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":55,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":43},"100551211","NCT06457139","Preventing T2DM After GDM With Immediate Postpartum Screening","Preventing Type 2 Diabetes Mellitus After Gestational Diabetes Mellitus With Immediate Postpartum Screening","Inclusion Criteria:\n\n* pregnancy complicated by GDM as diagnosed with traditional two step testing in the third trimester according to Carpenter-Coustan Criteria\n* receiving prenatal care at UMASS Memorial and plans to deliver at UMASS Memorial\n* able and willing to provide informed consent\n* ability to complete immediate in hospital postpartum glucose testing\n* have evidence of impaired glucose metabolism defined as fasting glucose value of ≥126 mg\u002FdL or 2-hour glucose value of ≥200 mg\u002FdL\n\nExclusion Criteria:\n\n* known diagnosis of pre-existing pre-gestational diabetes in pregnancy\n* inability to complete oral glucose tolerance test (e.g. gastric bypass surgery history, gastric dumping syndrome history, vomiting of oral glucose tolerance test) in pregnancy or immediately postpartum\n* systemic steroid use","FEMALE",{"count":556,"type":22},116,[57],"The overall goal of this proposal is to create and test an implementation protocol for in-hospital immediate postpartum diabetes screening for postpartum patients with pregnancies affected by GDM.",[560,26],"Gestational Diabetes",[161],{"date":334,"type":35},{"date":564,"type":35},"2025-06-01",{"date":566,"type":22},"2027-12-01",{"name":568,"class":42},"University of Massachusetts, Worcester",{"id":570,"slug":4,"hasResults":11,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":55,"phases":577,"briefSummary":578,"conditions":579,"keywords":580,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":586,"locationsCount":43},"100644231","NCT07666581","Influence of the Use of Specific Nutritional Formulas on Time in Range in Patients With Type 2 Diabetes","Influence of the Use of Specific Nutritional Formulas for Diabetes on Time in Range in Patients With Type 2 Diabetes Mellitus With Obesity by Freestyle Continuous Glucose Monitoring","Inclusion criteria:\n\n* Patients over 18 years of age.\n* Diagnosis of diabetes mellitus type 2.\n* HbA1c \\>7% to \\\u003C11%.\n* BMI \\>27 kg\u002Fmt2 \\\u003C35 kg\u002Fmt2\n* Current use of continuous glucose monitoring with adherence greater than 70%.\n* Access to technology to download data from CGM in a timely manner.\n* Ability to follow the study protocol and provide informed consent (Appendix 3).\n\nExclusion criteria:\n\n* Change in antidiabetic medication in the last 3 months.\n* Pregnancy or lactation or planning to become pregnant during the study period.\n* Acute decompensation of diabetes in the past 3 months.\n* Participation in another clinical trial.\n* Use of glucocorticoids or insulin in the past 3 months or planned use in the coming months.\n* Initiation of treatment with oral or injectable GLP-1 analogues 3 months prior to enrollment.\n* History of bariatric surgery or gastrointestinal pathology associated with malabsorption syndromes.",{"count":576,"type":22},198,[57],"Who can participate?\n\nIndividuals may be eligible to join this study if they meet the following criteria:\n\n* Are 18 years or older.\n* Have Type 2 diabetes with an A1c level higher than 7%.\n* Have a Body Mass Index (BMI) between 27 and 35 (considered overweight or Class 1 obesity).\n* Have used a continuous glucose monitor (CGM) successfully in the past.\n\nHow the study works:\n\nIf eligible individuals decide to join and sign the consent form, a computer will randomly assign them into one of two groups:\n\nThe Formula Group: Participants will replace their usual breakfast and one snack with a specific diabetes nutritional drink (Glucerna®).\n\nThe Standard Diet Group: Participants will follow a standard low-calorie meal plan without using the nutritional drink.\n\nBoth groups will aim for a specific daily calorie goal (1,200-1,500 for women; 1,500-1,800 for men) and will receive expert nutritional counseling.\n\nMonitoring and Follow-up\n\nOver the course of 3 months, close contact will be maintained to support participants:\n\nEvery 2 weeks: A nutrition expert will call participants to check on their diet and help with their glucose monitor.\n\nEvery month: Participants will meet with the study team in person to review glucose monitor data.\n\nTests: At the start and end of the study, weight, body composition, blood sugar (A1c), and cholesterol levels will be measured to see how the plans worked.",[26,251,519],[26,28,581,519],"Continuos Glucose Monitoring","2026-06-18",{"date":334,"type":35},{"date":71,"type":22},{"date":209,"type":22},{"name":528,"class":42},""]